ARWR FY2025 SEC EDGAR DEF 14A #64 of 168 in industry

Arrowhead Pharmaceuticals, Inc. CEO pay ratio

The CEO earned $9.0M in FY2025 against median worker pay of $163,062 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-01-27
Industry
Chemicals & Pharmaceuticals
Industry rank
#64/168

Data updated August 2026

Subscribe to Arrowhead Pharmaceuticals, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
55:1
Moderate (Scale: 0–1000:1)
CEO pay
$9.0M
Median worker
$163,062

Answer first

Arrowhead Pharmaceuticals, Inc.'s FY2025 CEO total of $9.0M ranks #604 of 1,423 complete filings; its 55:1 pay ratio ranks #934. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $163,062. Industry placement uses the FY2025 SIC-28 peer cohort (# 64 of 168, 63rd percentile - above the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#604
$9.0M of 1,423 FY2025
Ratio rank
#934
55:1 of 1,423
Industry pct
63rd
above the industry median pay ratio

How Arrowhead Pharmaceuticals, Inc. ranks nationally

Arrowhead Pharmaceuticals, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$8,968,410 Top 42% higher than 58% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). This entry sits in this band. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Arrowhead Pharmaceuticals, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($9.0M) against pay ratio (55:1) for Arrowhead Pharmaceuticals, Inc. (marked) and its 4 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both5481389.46394656.773079248221191.39134458.641.1:146.0:151:156.0:160.9:1CEO total payPay ratio (CEO : median worker)Arrowhead Pharmaceuticals, Inc., CEO total pay: 8968410 · Pay ratio (CEO : median worker): 55:1Arrowhead Pharmaceuticals, Inc.Prestige Consumer Healthcare Inc., CEO total pay: 6004547 · Pay ratio (CEO : median worker): 54:1Prestige Consumer Healthcare Inc.AbCellera Biologics Inc., CEO total pay: 6350188 · Pay ratio (CEO : median worker): 52:1AbCellera Biologics Inc.AdvanSix Inc., CEO total pay: 5647438 · Pay ratio (CEO : median worker): 51:1AdvanSix Inc.Myriad Genetics Inc, CEO total pay: 5844420 · Pay ratio (CEO : median worker): 60:1Myriad Genetics Inc
Arrowhead Pharmaceuticals, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Arrowhead Pharmaceuticals, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Arrowhead Pharmaceuticals, Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2023–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
55:1
FY2025
vs prior FY
-15:1
from FY2024 70:1
CEO $ YoY
-27%
$9.0M latest
Filings shown
3
FY2023–2025
Arrowhead Pharmaceuticals, Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2023 $9.9M - $166,990 59:1 -
2024 $12.2M +24% $174,364 70:1 +11:1
2025 $9.0M -27% $163,062 55:1 -15:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 879407, FY2023–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
55:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$9.0M
Companies in Industry
168
vs. Industry Median
Above
#64 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Arrowhead Pharmaceuticals, Inc.: MODEST · HEAVY pay ratio

Arrowhead Pharmaceuticals, Inc. disclosed 55:1 CEO-to-worker pay and $9.0M CEO total in FY2025. the CEO earned 55× the median employee ($163,062) in FY2025.

Median employee $163,062 (ELITE-MED); MODEST · HEAVY stamps put about 55 median-wage years per CEO year.

CEO Total Pay

$9.0M

FY2025 Summary Compensation, above median

Pay Ratio

55:1

Near industry median

What FY2025 shows for Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. disclosed 55:1 CEO-to-worker pay and $9.0M CEO total in FY2025. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Arrowhead Pharmaceuticals, Inc.'s $9.0M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #604 and ratio rank #934 split - treat 55:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$9.0M
Median Employee Pay
$163,062
Pay Ratio
55:1
Filing Date
2026-01-27

Company Info

Ticker
ARWR
CIK
879407
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 879407, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Arrowhead Pharmaceuticals, Inc. disclosed 55:1 CEO-to-worker pay and $9.0M CEO total in FY2025.

Read with Arrowhead Pharmaceuticals, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · HEAVY · ELITE-MED.

Douglas Emmett Inc · HEAVY

ABS(ceo_total_comp) peer at $9.0M (Δ $20K heavier vs Arrowhead Pharmaceuticals, Inc.); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Iridium Communications Inc. · HEAVY

ABS(ceo_total_comp) peer at $9.0M (Δ $45K heavier vs Arrowhead Pharmaceuticals, Inc.); MODEST · ELITE-MED vs this page's MODEST · HEAVY · ELITE-MED.
Rollins Inc · HEAVY

ABS(ceo_total_comp) peer at $8.9M (Δ $48K lighter vs Arrowhead Pharmaceuticals, Inc.); MID · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
Hunt J B Transport Services Inc · HEAVY

ABS(ceo_total_comp) peer at $9.0M (Δ $51K heavier vs Arrowhead Pharmaceuticals, Inc.); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Prestige Consumer Healthcare Inc. (SIC 28 pole)

Prestige Consumer Healthcare Inc. stamps MODEST · HEAVY nearest in-SIC by ABS(pay_ratio) to Arrowhead Pharmaceuticals, Inc.'s MODEST filing.
National dual ranks · #604/#934

Arrowhead Pharmaceuticals, Inc.'s FY2025 package sits #604 by CEO dollars and #934 by ratio under HEAVY · MODEST.
Ratio primer · MODEST

Arrowhead Pharmaceuticals, Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Arrowhead Pharmaceuticals, Inc. (CIK 879407), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.